ITonis

ITonis EPS Growth

The EPS Growth of ITonis (ITNS) as of Nov 2, 2026 is -17.59 %. In the previous year, EPS Growth was 74.87 % — a change of -123.50% (lower).

EPS Growth

-17.59 %

YoY

-123.50%

Last updated:

EPS Growth of ITonis is 2025 -17.59 % . EPS Growth of ITonis was 2024 74.87 % . It decreases by -123.50% lower compared to the previous year.

The ITonis EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
81.38 USD
Jan 1, 2019
15.00 USD
Jan 1, 2020
20.51 USD
Jan 1, 2021
-47.17 USD
Jan 1, 2022
89.39 USD
Jan 1, 2023
-405.92 USD
Jan 1, 2024
74.87 USD
Jan 1, 2025
-17.59 USD
The ITonis EPS Growth history
YEAREPS GrowthYoY
-17.59 %-123.50%
74.87 %-118.44%
-405.92 %-554.09%
89.39 %-289.52%
-47.17 %-329.97%
20.51 %+36.71%
15.00 %-81.56%
81.38 %+76.71%
46.05 %+465.22%
8.15 %-75.66%
33.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

EPS Growth of ITonis is -17.59 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth ITonis since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's ITonis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ITonis

All Key Metrics — ITonis